Project Grant R21CA297068
Award Date
9/1/24
Completion Date
11/30/26
Dollars Obligated
$427K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas MD Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) in the context of colorectal cancer. The project aims to assess the impact of tumor growth and surgical resection on the subsequent development of pain hypersensitivity in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $391,325.00 to the University of Arizona to develop a new portable confocal microscope that can rapidly image Meissner's corpuscles, which are microscopic nerve endings associated with chemotherapy-induced peripheral neuropathy (CIPN). The goals are to evaluate the clinical utility of this portable confocal microscopy (PCM) technology for assessing CIPN, and to develop deep...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University provides $601,091 over a 5-year period starting April 1, 2025 to research damage-associated molecular patterns and their role in paclitaxel-induced peripheral neuropathy. The research aims to characterize the mechanism by which the inflammatory protein S100A9 contributes to this debilitating side effect of the chemotherapy drug paclitaxel, determine an optimal...
This $1,239,420 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports a longitudinal observational study on the role of interoception (the brain's processing of bodily sensations) in chemotherapy-induced peripheral neuropathy (CIPN). The study will assess changes in interoception and its relationship to CIPN symptoms in 120 patients with breast or gastrointestinal cancer before, during, and after receiving taxane- or...
The National Institute on Aging (NIA) awarded a $589,106 Project Grant (CFDA 93.866 - Aging Research) to Washington University in St. Louis, Missouri, with a period of performance from June 1, 2025 to March 31, 2030. The grant supports research to elucidate the role of senescent stromal cells in driving chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect experienced by up to 90% of cancer patients receiving taxane-based chemotherapies. The research aims to 1)...
This Project Grant award, with a total funding of $138,742, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The primary awardee, The Johns Hopkins University, will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that are altered by combination immunotherapy treatments in pancreatic ductal adenocarcinoma (PDAC). Additionally, the award will support experiments...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) Division. The $179,403 grant, awarded on April 1, 2025, will fund research to develop novel flupirtine analogue compounds that can effectively relieve chemotherapy-induced neuropathic pain (CINP) in cancer patients while addressing the safety concerns associated with the parent flupirtine...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $181,448 to Virginia Commonwealth University (VCU) to research the use of the NLRP3 inflammasome inhibitor dapansutrile for treating chemotherapy-induced peripheral neuropathy (CIPN). The project aims to determine if dapansutrile can alleviate and prevent CIPN caused by paclitaxel and cisplatin chemotherapy in mouse models, including both naive and...
This $255,769 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports the development of a novel proxy-report survey to screen for chemotherapy-induced peripheral neuropathy (CIPN) in young children aged 1-5 years. The grant recipient, Yale University, will 1) use qualitative research methods to develop survey items to screen for CIPN symptoms, 2) prospectively evaluate the survey's psychometric properties, and 3) collect preliminary...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...